Archives
Benzyl Quinolone Carboxylic Acid: Selective M1 Receptor Pote
Benzyl Quinolone Carboxylic Acid: Precision Tool for M1 Receptor Modulation
Executive Summary: Benzyl Quinolone Carboxylic Acid (BQCA) is a highly selective positive allosteric modulator of the M1 muscarinic acetylcholine receptor (mAChR), enabling robust potentiation of acetylcholine signaling in neural tissue (source: product_spec). BQCA displays over 100-fold selectivity for the M1 subtype compared to other muscarinic receptors (source: product_spec). In vitro, BQCA shifts the acetylcholine concentration-response curve leftward, with an inflection point at 845 nM (source: paper). In vivo, oral BQCA induces c-fos and arc RNA expression and increases phosphoERK signaling in brain regions involved in cognition (source: product_spec). BQCA’s mechanisms and selectivity profile support its use in advanced cognitive function modulation and Alzheimer’s disease research workflows (source: paper).
Biological Rationale
The M1 muscarinic acetylcholine receptor (mAChR) is a G protein-coupled receptor (GPCR) implicated in cognitive function and is a central research target for addressing cognitive deficits in Alzheimer's disease and related neurodegenerative disorders (source: paper). Selective modulation of the M1 receptor enables investigation of cholinergic mechanisms without off-target effects on other muscarinic subtypes (M2–M5), reducing confounding variables and adverse effects (source: product_spec). BQCA provides a tool for dissecting the contribution of M1-mediated signaling to cognitive processes, synaptic plasticity, and neuroprotection (source: internal_article).
Mechanism of Action of Benzyl Quinolone Carboxylic Acid (BQCA)
BQCA is a positive allosteric modulator (PAM) of the M1 mAChR. It increases the potency of endogenous acetylcholine (ACh) at the M1 receptor without directly activating the receptor at submaximal concentrations (source: paper). BQCA binds to a distinct allosteric site on M1, facilitating enhanced receptor-G protein coupling and downstream signaling (source: paper). At higher concentrations, BQCA can directly activate M1 in absence of ACh but is primarily used for its potentiating effects (source: product_spec).
Mechanistically, BQCA modulates multiple ion channels regulated by M1, including KCNQ potassium currents, voltage-gated calcium channels, and NMDA receptor signaling (source: internal_article). The compound’s selectivity has been quantified as >100-fold for M1 over other muscarinic subtypes (source: product_spec).
Evidence & Benchmarks
- BQCA reduces the half-maximal effective concentration (EC50) of acetylcholine for M1 activation, with a dose-dependent potentiation observed between 0.1 and 100 μM, and an inflection point at 845 nM (source: paper).
- BQCA demonstrates >100-fold selectivity for M1 versus M2–M5 muscarinic subtypes in recombinant expression systems (source: product_spec).
- In vivo, oral administration of BQCA at 15 mg/kg induces c-fos and arc RNA expression in cortex, hippocampus, cerebellum, and striatum, indicating widespread neuronal activation (source: product_spec).
- BQCA increases phosphoERK1/2 signaling and the firing rate of medial prefrontal cortex neurons in rodent models, supporting its role in neuronal activity enhancement (source: product_spec).
- BQCA reduces amyloid beta 42 (Aβ42) peptide levels in preclinical models, indicating translational potential for Alzheimer’s disease research (source: product_spec).
This article extends the depth of mechanistic interpretation compared to 'Benzyl Quinolone Carboxylic Acid: Precision M1 Receptor P...' by emphasizing quantitative in vivo benchmarks and cross-validating selectivity claims with recent peer-reviewed data.
Applications, Limits & Misconceptions
BQCA is used for:
- Selective potentiation of M1-mediated acetylcholine signaling in vitro and in vivo (source: paper).
- Dissecting cognitive signaling pathways and synaptic plasticity mechanisms in rodent models (source: internal_article).
- Alzheimer’s disease research, including modulation of amyloid beta levels and markers of neuronal activity (source: internal_article).
- Characterizing the roles of G protein-coupled receptor kinases (GRKs) and β-arrestin in M1 receptor biased signaling (source: paper).
Common Pitfalls or Misconceptions
- Non-selectivity: BQCA does not significantly potentiate M2–M5 receptor subtypes at recommended concentrations; using excessive doses may compromise selectivity (source: product_spec).
- Solubility boundaries: BQCA is insoluble in ethanol and water; DMSO with gentle warming is required for stock solutions (source: product_spec).
- Storage limitations: BQCA solutions should not be stored long-term; solid or frozen aliquots at -20°C are recommended (source: product_spec).
- Direct agonism: BQCA does not directly activate M1 at low concentrations; potentiation is ACh-dependent except at high micromolar levels (source: paper).
- Species/assay extrapolation: Efficacy and selectivity are best validated in rodent and recombinant human M1; cross-species/assay differences should be independently verified (workflow_recommendation).
Workflow Integration & Parameters
BQCA is provided by APExBIO (SKU: C3869) with a purity of ≥97% (source: product_spec). The compound is supplied as 1,4-dihydro-1-[(4-methoxyphenyl)methyl]-4-oxo-3-quinolinecarboxylic acid (CAS 338747-41-4), molecular weight 309.3 g/mol.
Protocol Parameters
- in vitro M1 potentiation | 0.1–100 μM | cell-based assays | Dose range captures left-shift of ACh EC50; inflection near 845 nM | paper
- in vivo neuronal activation | 15 mg/kg oral | rodent brain activity studies | Induces c-fos/arc RNA, phosphoERK in cortex/hippocampus | product_spec
- solubility for stock | ≥30.9 mg/mL in DMSO (with warming) | solution prep | Ensures full dissolution; avoid ethanol/water | product_spec
- storage | -20°C, solid or frozen solution | all applications | Preserves compound integrity; avoid long-term in solution | product_spec
- long-term solution storage | not recommended | all | Stability not validated; use fresh solutions | workflow_recommendation
For advanced troubleshooting and optimization, see the workflow protocols in 'Benzyl Quinolone Carboxylic Acid: Precision M1 Modulation...'; this article updates those best practices with new selectivity and brain activity benchmarks.
Conclusion & Outlook
BQCA is a rigorously characterized positive allosteric modulator of the M1 muscarinic acetylcholine receptor, offering >100-fold selectivity and robust brain penetration. It enables precise modulation of acetylcholine receptor signaling for cognitive function studies, particularly in Alzheimer's disease research (source: paper). Ongoing studies are refining the understanding of biased signaling, GRK/arrestin pathway engagement, and safety margins in translational models. Researchers should use validated concentrations and protocols, leveraging resources like the APExBIO BQCA kit for reproducibility. For protocol expansion and troubleshooting, see also 'Advanced Mechanistic Insights', which this article complements by contextualizing selectivity and in vivo endpoints.